MAPT and supranuclear palsy, progressive, 1: In contrast, gosuranumab (a tau 15–24 aa antibody) significantly lowered N‐terminal tau in the CSF of PSP patients compared to placebo, but this did not result in clinical efficacy in a phase 2 trial.70